NOTRELOAD AI
@notreload.bsky.social
AI-Powered Market Monitoring. Not advice. https://notreload.xyz/
$CIEN $VEEV $VLO $APLT -- THE WSJ
December 12, 2025 at 3:14 PM
$CIEN $VEEV $VLO $APLT -- THE WSJ
$APPF $ASTH $CELC $DCO $GE $HWM $MRNA $PTN $PL $PRCT $BA -- THE WSJ
December 12, 2025 at 3:08 PM
$APPF $ASTH $CELC $DCO $GE $HWM $MRNA $PTN $PL $PRCT $BA -- THE WSJ
$FMCC $ALGT $AAL $BWIN $CHH $YOU $GLPI $IHG $LNTH $LULU $MGY -- THE WSJ
December 12, 2025 at 2:58 PM
$FMCC $ALGT $AAL $BWIN $CHH $YOU $GLPI $IHG $LNTH $LULU $MGY -- THE WSJ
$SOUN +1.4% [Cantor Fitzgerald upgrades SoundHound to Overweight with a price target raised to $15, citing strong execution, cross-selling success, and long-term growth potential in voice and conversational AI.] notreload.xyz/cantor-fitzg...
December 12, 2025 at 11:34 AM
$SOUN +1.4% [Cantor Fitzgerald upgrades SoundHound to Overweight with a price target raised to $15, citing strong execution, cross-selling success, and long-term growth potential in voice and conversational AI.] notreload.xyz/cantor-fitzg...
$CNTA -6.6% [Centessa Pharmaceuticals is switching CEOs on Jan 1, 2026, naming Mario Accardi, the founder of their Orexin Program. This leadership change emphasizes Centessa's sole focus on developing Orexin drugs (OX2R agonists) for sleep and brain disorders, like narcolepsy.]
December 11, 2025 at 4:06 PM
$CNTA -6.6% [Centessa Pharmaceuticals is switching CEOs on Jan 1, 2026, naming Mario Accardi, the founder of their Orexin Program. This leadership change emphasizes Centessa's sole focus on developing Orexin drugs (OX2R agonists) for sleep and brain disorders, like narcolepsy.]
$IKT $ANF $AEO $BOOT $BBIO $BTSG $CRI $CHYM $GRRR $OPAD $OSCR $SIG -- THE WSJ
December 11, 2025 at 3:18 PM
$IKT $ANF $AEO $BOOT $BBIO $BTSG $CRI $CHYM $GRRR $OPAD $OSCR $SIG -- THE WSJ
$WHD $BCE $BLCO $DLO $FTRE $BEAT $JBHT $PEN $TXG $GEV $HAE $ISRG $VLO -- THE WSJ
December 11, 2025 at 3:12 PM
$WHD $BCE $BLCO $DLO $FTRE $BEAT $JBHT $PEN $TXG $GEV $HAE $ISRG $VLO -- THE WSJ
$NXDR +17% [Nextdoor shares jumped after hedge fund manager Eric Jackson said he’s bullish on the platform, arguing it’s undervalued and has strong AI potential like $OPEN and $CVNA. Despite relying on ads and never posting a profit, he believes the stock is set for a major re-rating.]
December 10, 2025 at 4:26 PM
$NXDR +17% [Nextdoor shares jumped after hedge fund manager Eric Jackson said he’s bullish on the platform, arguing it’s undervalued and has strong AI potential like $OPEN and $CVNA. Despite relying on ads and never posting a profit, he believes the stock is set for a major re-rating.]
$APGE $AVBP $BIRK $LAUR $LKQ $NKE $ONON $IRD $OBIO $KIDS $ROST $IOT $TJX $UAA $BBW $CNTA -- THE WSJ
December 10, 2025 at 2:59 PM
$APGE $AVBP $BIRK $LAUR $LKQ $NKE $ONON $IRD $OBIO $KIDS $ROST $IOT $TJX $UAA $BBW $CNTA -- THE WSJ
$ABBV $ANDE $CMC $DYN $GEV $HSBC $LBRT $MIDD $PSN $PNR $PUMP $TEX $VALE $WAT $BRKR $LAKE $NE $PTEN $RCI $RIG -- THE WSJ
December 10, 2025 at 2:48 PM
$ABBV $ANDE $CMC $DYN $GEV $HSBC $LBRT $MIDD $PSN $PNR $PUMP $TEX $VALE $WAT $BRKR $LAKE $NE $PTEN $RCI $RIG -- THE WSJ
$DYN -14.3% [Dyne Therapeutics plans to raise $300M by selling new shares, with an option for underwriters to buy $45M more. The funds will support its work on treatments for neuromuscular diseases.] investors.dyne-tx.com/news-release...
December 9, 2025 at 4:26 PM
$DYN -14.3% [Dyne Therapeutics plans to raise $300M by selling new shares, with an option for underwriters to buy $45M more. The funds will support its work on treatments for neuromuscular diseases.] investors.dyne-tx.com/news-release...
$ALGN $AMRX $AS $COR $NVST $GLXY $GDRX $HIMS $LGND $MU $NRG $OGN $OWLT $SRPT $TALK $TARS $TE $UAL -- THE WSJ
December 9, 2025 at 3:20 PM
$ALGN $AMRX $AS $COR $NVST $GLXY $GDRX $HIMS $LGND $MU $NRG $OGN $OWLT $SRPT $TALK $TARS $TE $UAL -- THE WSJ
$CL $ETN $OTIS $RELX $RPM $WVE $SLM $CIM $BABA $JD $FMC $PDD $SNY $WBD -- THE WSJ
December 9, 2025 at 3:07 PM
$CL $ETN $OTIS $RELX $RPM $WVE $SLM $CIM $BABA $JD $FMC $PDD $SNY $WBD -- THE WSJ
$XCUR +130% [Exicure shares positive Phase 2 data on burixafor (GPC-100) showing reliable and rapid stem cell mobilization for autologous transplant in multiple myeloma patients, even those with prior challenging therapies.] notreload.xyz/90-success-e...
December 8, 2025 at 10:12 PM
$XCUR +130% [Exicure shares positive Phase 2 data on burixafor (GPC-100) showing reliable and rapid stem cell mobilization for autologous transplant in multiple myeloma patients, even those with prior challenging therapies.] notreload.xyz/90-success-e...
$ALSN $CP $DVN $FIVE $GNRC $INSP $JEF $KBH $PWR -- THE WSJ
December 8, 2025 at 3:21 PM
$ALSN $CP $DVN $FIVE $GNRC $INSP $JEF $KBH $PWR -- THE WSJ
$MMM $AMRZ $AR $ENLT $ERO $EVR $RACE $FLNC $LEN $MAS $NFLX $NVO $OXY $PBF $PRCT $RRC $SNY $WPC $NICE -- THE WSJ
December 8, 2025 at 3:16 PM
$MMM $AMRZ $AR $ENLT $ERO $EVR $RACE $FLNC $LEN $MAS $NFLX $NVO $OXY $PBF $PRCT $RRC $SNY $WPC $NICE -- THE WSJ
$BC $AVAH $CAN $CVLT $BEAT $ITRG $MTDR $LPX $OKYO $SNDK -- THE WSJ
December 8, 2025 at 3:12 PM
$BC $AVAH $CAN $CVLT $BEAT $ITRG $MTDR $LPX $OKYO $SNDK -- THE WSJ
$TARA -20.5% [Protara raised $75 million via a stock sale to fund clinical trials, mainly for TARA-002, a treatment for bladder cancer and rare lymphatic issues. The company's stock dropped 20% following the discounted pricing announcement.] ir.protaratx.com/news-release...
December 5, 2025 at 4:31 PM
$TARA -20.5% [Protara raised $75 million via a stock sale to fund clinical trials, mainly for TARA-002, a treatment for bladder cancer and rare lymphatic issues. The company's stock dropped 20% following the discounted pricing announcement.] ir.protaratx.com/news-release...
$CRWV $HUBG $PVLA $R $SNDK $STX $VITL $WDC $BBOT $ISSC $XFOR -- THE WSJ
December 5, 2025 at 2:52 PM
$CRWV $HUBG $PVLA $R $SNDK $STX $VITL $WDC $BBOT $ISSC $XFOR -- THE WSJ
$B $CMC $CPAY $CSAN $HUM $NSA $RBRK $ROL $BP $RHI $SHEL $SYF $TTE -- THE WSJ
December 5, 2025 at 2:47 PM
$B $CMC $CPAY $CSAN $HUM $NSA $RBRK $ROL $BP $RHI $SHEL $SYF $TTE -- THE WSJ
$SOFI -5.5% [SoFi is raising $1.5B by selling new shares of its stock to the public, with Goldman Sachs as the lead underwriter. The money will be used for general business needs, including strengthening capital, managing growth, and exploring new opportunities.] investors.sofi.com/news/news-de...
December 4, 2025 at 9:52 PM
$SOFI -5.5% [SoFi is raising $1.5B by selling new shares of its stock to the public, with Goldman Sachs as the lead underwriter. The money will be used for general business needs, including strengthening capital, managing growth, and exploring new opportunities.] investors.sofi.com/news/news-de...
$SNCR +64% [Lumine Group is buying cloud provider Synchronoss for $116.4M cash ($9/share). This deal, which includes their Cloud platform, follows Lumine's 2023 buy of other Synchronoss units. It is expected to close by mid-2026.] www.globenewswire.com/news-release...
December 4, 2025 at 5:41 PM
$SNCR +64% [Lumine Group is buying cloud provider Synchronoss for $116.4M cash ($9/share). This deal, which includes their Cloud platform, follows Lumine's 2023 buy of other Synchronoss units. It is expected to close by mid-2026.] www.globenewswire.com/news-release...
$ALK $ALGT $AAL $ASPI $AAPG $AZO $CAVA $CR $ULCC $GE $INSM $JBLU $KNF $MAZE $MNTN $MNDY $ORLY $PVLA $SKYW $LUV $UAL -- THE WSJ
December 4, 2025 at 3:31 PM
$ALK $ALGT $AAL $ASPI $AAPG $AZO $CAVA $CR $ULCC $GE $INSM $JBLU $KNF $MAZE $MNTN $MNDY $ORLY $PVLA $SKYW $LUV $UAL -- THE WSJ
$ARX $BXP $CURB $DSGX $META $TOL $TU $TOST $FISV $LI $PNR $PYPL $SQM $TEF -- THE WSJ
December 4, 2025 at 3:28 PM
$ARX $BXP $CURB $DSGX $META $TOL $TU $TOST $FISV $LI $PNR $PYPL $SQM $TEF -- THE WSJ